I
Isabel Borges
Researcher at University of Geneva
Publications - 4
Citations - 424
Isabel Borges is an academic researcher from University of Geneva. The author has contributed to research in topics: Wnt signaling pathway & Homeobox protein NANOG. The author has an hindex of 4, co-authored 4 publications receiving 364 citations. Previous affiliations of Isabel Borges include Carnegie Mellon University.
Papers
More filters
Journal ArticleDOI
NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐functional network with GLI1 and p53
Marie Zbinden,Arnaud Duquet,Aiala Lorente-Trigos,Sandra-Nadia Ngwabyt,Isabel Borges,Ariel Ruiz i Altaba +5 more
TL;DR: The data establish NANOG as a novel HH‐GLI mediator essential for GBMs and propose that this function is conserved and that tumour growth and stem cell behaviour rely on the status of a functional GLI1‐NANOG‐p53 network.
Journal ArticleDOI
The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer
Alice Melotti,Christophe Mas,Monika Kuciak,Aiala Lorente-Trigos,Isabel Borges,Ariel Ruiz i Altaba +5 more
TL;DR: It is reported that Ivermectin inhibits the expression of WNT‐TCF targets, mimicking dnTCF, and that its low concentration effects are rescued by direct activation by TCFVP16, indicating its action involves protein phosphatases.
Journal ArticleDOI
Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells.
Chandan Seth,Christophe Mas,Arwen Conod,Jens Mueller,Karsten Siems,Monika Kuciak,Isabel Borges,Ariel Ruiz i Altaba +7 more
TL;DR: Withanolide F is unique in that it imposes a long-lasting repression of tumor growth, WNT-TCF targets and cancer stem cell clonogenicity after drug treatment, and opens up the possibility to permanently repress essential signaling responses in cancer cells through limited treatments with small molecules.
Journal ArticleDOI
Chimeric NANOG repressors inhibit glioblastoma growth in vivo in a context-dependent manner.
TL;DR: The proof of principle for a strategy to directly repress the targets of a salient stemness and pluripotency factor: NANOG is provided, and the transcriptomes of cells expressing NANEP5 reveal multiple potential mediators of pro-tumorigenic NAN EP/NANOG action including intercellular signaling components.